The Latest Breaking News from Biogen

The drug Leqembi targets plaque buildup in the brain, and it is approved for people in the early stages of the disease.

Fortune 500 companies, including Salesforce and Microsoft, reacted to the Supreme Court's decision to reject affirmative action at U.S. colleges and universities.

Leqembi could become the first treatment of its kind to receive traditional approval from the FDA.

Starting this summer, Colorado's Prescription Drug Affordability Board will choose up to 18 high-cost drugs for review.

U.S. health regulators have approved a first-of-a-kind drug for a rare form of Lou Gehrig’s disease

The U.S. Veterans Health Administration will pay for some beneficiaries to get a new Alzheimer’s disease drug from Eisai Co. and Biogen Inc., positive news for a treatment that Eisai expects to bring in billions of dollar in sales in the next few years.

This month, the Food and Drug Administration approved a new drug, lecanemab, for the treatment of Alzheimer’s disease. The drug, sold under the brand name Leqembi, was developed by Japanese pharmaceutical company Eisai and will be marketed commercially in partnership with American pharmaceutical company Biogen. Biogen, notably, is the maker…

A treatment that improves Alzheimer’s disease would be a great advance, but Leqembi (lecanemab), which recently received accelerated approval from the FDA, is not that drug. Yes, lecanemab slows decline to an extent detectable on a test, but not to an extent that a relative or caretaker would notice. This…

The U.S. Food and Drug Administration approved the medication lecanemab, sold under the brand name Leqembi, on Jan. 6, 2023, through an “accelerated approval pathway” that fast-tracks promising clinical treatments for diseases in which there are no other currently effective options.